Genome-Centric Multimodal Data Integration in Personalised Cardiovascular Medicine.

Queen Mary University of London

Queen Mary University of London (QMUL) participates in NextGen through our William Harvey Research Institute (WHRI), an internationally acknowledged centre of excellence in the field of cardiovascular research and therapeutic innovation. Through Genomics to Mechanisms research, the WHRI vision is to deliver state-of-the-art treatments to 6 million Barts Health NHS Trust patients. Cardiovascular research programmes at the WHRI and the Barts Heart Centre are closely aligned to maximise our collective expertise and strengths in areas such as pharmacological and device development that lead to innovative clinical trials for the diagnosis and treatment of heart disease whilst offering a range of professional training opportunities. Combined, our strategic approach enables the development and delivery of world-leading clinical care. As part of the Faculty of Medicine and Dentistry at QMUL, we are one of the largest multidisciplinary pharmacological institutes in Europe with over 530 clinicians and scientists from 45 countries. Our innovative research environment and close collaboration with Barts Health NHS Trust and healthcare partners across East London gives us a unique opportunity to translate and extend basic and clinical research into therapeutics that benefit the local community and beyond.

QMUL co-ordinated the development of the NextGen proposal, and is the project’s scientific co-ordinator, leading the personalised medicine and regulatory work packages. QMUL will also develop multi-modal multi-omic AL/ML research outputs which will demonstrate the utility of NextGen tooling in removing barriers to data integration.